In short
- NewLimit wants to increase the healthy lifespan with the help of AI-driven celerprogramming.
- The B -round series brings total financing with more than $ 170 million, supported by Top Tech and VC names.
- The startup of the lifespan is part of a broader trend of billionaire-supported ventures.
NewLimit, a startup of biotechnology that was co-founded by Coinbase CEO Brian Armstrong, has collected $ 130 million in a B-financing round series to strengthen its ambitions to delay or even reverse aspects of human aging.
De Ronde, led by smaller Perkins, took participation in prominent recurring investors, including Founders Fund, Dimension Capital, Angel Investor Elad Gil, Y Combinator CEO Garry Tan and Stripe co-founder Patrick Collison, according to a rack.
New investors were former Github CEO Nat Friedman, former Machine Learning director Daniel Gross and Khosla Ventures. The increase brings the total financing of the startup to more than $ 170 million after a Serie A of $ 40 million in 2023.
Turn it around and turn it around
Armstrong launched NewLimit more than four years ago with former GV partner Blake Byers and stem cell researcher Jacob Kimmel.
The company strives for therapies that increase “healthy life expectancy” – how long someone can lead a healthy life, in contrast to life expectancy – by reprogramming the human epigenoom by changing how cells behave without changing their underlying DNA.
NewLimit described his mission as the treatment of aging itself, which called it the ‘meta director of almost every major human disease’.
“Once considered irreversible, the emerging science of epigenetic reprogramming has shown that aging is in fact malleable,” said it.
NewLimit is part of a growing movement among technical billionaires running software and fintech to the tempting prospect of biological immortality.
Billionaire obsession
The company fits square in a wave of startups supported by Silicon Valley with a long service life in the hope of solving the age -old problem of aging itself with advanced technology and a lot of money.
OpenAI CEO Sam Altman is one of the largest financiers of retro-cinemese, who strives for age. Founder of Amazon Jeff Bezos has thrown his weight behind another company, Altos Labs, aimed at “the disease, injury and the handicaps that take place throughout life by restoring the health and resilience of the cells through cell rejuvenation.”
In the meantime, Methuselah Foundation, a non-profit organization named after the surviving figure of the Bible (he would died at the age of 969), the ambitious goal of making the new 50 by 2030. ” It counts PayPal-MEDE founder Peter Thiel and Ethereum’s Vitalik Buterin among his donors.
The Newlimit strategy combines large-scale genomics with AI-driven analysis.
The “Discovery Engine” tests thousands of reprogramming combinations on human cells and studies the effects.
The company’s machine learning models help to choose which mobile tweaks they should pursue in the next cycle, so that random study and error are avoided in favor of targeted experiments. It does not have to perform human tests yet.
“We have built technology to conduct the greatest experiments in the field,” the company said in the statement. “Our bet is that this combination of AI and scaled Genomics can unlock medicines that give us all healthy years.”
Edited by Sebastian Sinclair
Generally intelligent Newsletter
A weekly AI trip told by Gen, a generative AI model.
